NCT04731064

Brief Summary

The treatment of hemorrhoidal disease involves both instrumental and surgical techniques (hemorrhoidectomy and hemorrhoidopexy). In 1995, a Japanese author proposed a new treatment technique for stage II (spontaneous reintegration prolapse) or III (digital reintegration prolapse) disease, based on Doppler identification of low perirectal arteries followed by their ligation, via a specific windowed rectoscope. Later, a further modification appeared, allowing patients to be treated at more advanced stages, adding vertical mucopexy to the ligatures along the main bundles. The pathophysiology of hemorrhoidal disease is based on a vascular theory (opening of arteriovenous shunts) and on a mechanical theory (distension of the supporting tissue). Hemorrhoidectomy responds to the first, hemorrhoidopexy to the second. The HAL (Hemorrhoidal Artery Ligation) - RAR (Recto-Anal Repair) technique seeks to treat both vascular (by ligation of the nourishing arteries) and mechanical (by mucopexy of prolapsed bundles) components. The technique first spread to Germany, Russia, Italy, Spain, Australia and England. It has been popularized in France by some authors.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2023

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 28, 2021

Completed
1 day until next milestone

First Posted

Study publicly available on registry

January 29, 2021

Completed
1.9 years until next milestone

Study Start

First participant enrolled

January 6, 2023

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2024

Completed
Last Updated

May 14, 2024

Status Verified

May 1, 2024

Enrollment Period

1.5 years

First QC Date

January 28, 2021

Last Update Submit

May 13, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • The rate of recurrence leading to a re-intervention within 10 years of the intervention.

    10 years

Interventions

The patient is operated on in the first perineal position, under general anesthesia or under locoregional or even local anesthesia, after rectal preparation by simple enema. The HAL equipment included a disposable transparent rectoscope fitted near its end with a centimeter window through which wire stitch ligatures will be made. A light source facilitating the exposure of the internal face of the rectum and a Doppler transducer secured to the base of the rectoscope containing the Doppler system. Everything is connected to a generator which transmits Doppler noises to the surgeon. A printer on the generator makes it possible to map ligatures and note the depth of linked arteries. Equipment includes needle holder, knot pusher, scissors and dissecting forceps. The material for HAL is identical, except for the disposable rectoscope which is more indented at its end and on one side.

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All adult patients operated for a disease in the digestive surgery and emergency departments will be included, provided they are not opposed.

You may qualify if:

  • Patient operated for hemorrhoidal disease for 10 or more
  • Age 18 and over
  • Informed patients

You may not qualify if:

  • Patient opposition
  • Minor patient

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU Grenoble-alpes

Grenoble, France

RECRUITING

MeSH Terms

Interventions

Retinoic Acid Receptor alpha

Intervention Hierarchy (Ancestors)

Receptors, Retinoic AcidReceptors, Cytoplasmic and NuclearProteinsAmino Acids, Peptides, and ProteinsTranscription Factors

Study Officials

  • Giorgia Mastronicola

    CHU Grenoble Alpes

    PRINCIPAL INVESTIGATOR
  • Jean Luc FAUCHERON, MD-PhD

    CHU Grenoble Alpes

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 28, 2021

First Posted

January 29, 2021

Study Start

January 6, 2023

Primary Completion

June 30, 2024

Study Completion

June 30, 2024

Last Updated

May 14, 2024

Record last verified: 2024-05

Locations